Verici Dx (Verici Dx) Scaled Net Operating Assets

: 0.14 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Verici Dx's operating assets for the quarter that ended in Jun. 2023 was $4.10 Mil. Verici Dx's operating liabilities for the quarter that ended in Jun. 2023 was $2.04 Mil. Verici Dx's Total Assets for the quarter that ended in Dec. 2022 was $14.31 Mil. Therefore, Verici Dx's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2023 was 0.14.

Verici Dx Scaled Net Operating Assets Historical Data

The historical data trend for Verici Dx's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Scaled Net Operating Assets

0.10

0.08

0.17

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23
Scaled Net Operating Assets	0.15	0.09	0.14	0.12	0.14

Competitive Comparison

For the Diagnostics & Research subindustry, Verici Dx's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verici Dx Scaled Net Operating Assets Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Verici Dx's Scaled Net Operating Assets falls into.

Verici Dx Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Verici Dx's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2022 )
=	(Operating Assets (A: Dec. 2022 )	-	Operating Liabilities (A: Dec. 2022 ))	/	Total Assets (A: Dec. 2021 )
=	(4.5	-	2.096)	/	13.789
=	0.17

where

	Operating Assets		(A: Dec. 2022 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	14.305	-	9.805
=	4.5

	Operating Liabilities		(A: Dec. 2022 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	2.796	-	0.544	-	0.156
=	2.096

Verici Dx's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Jun. 2023 )
=	(Operating Assets (Q: Jun. 2023 )	-	Operating Liabilities (Q: Jun. 2023 ))	/	Total Assets (Q: Dec. 2022 )
=	(4.104	-	2.044)	/	14.305
=	0.14

where

	Operating Assets		(Q: Jun. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	9.353	-	5.249
=	4.104

	Operating Liabilities		(Q: Jun. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	2.665	-	0.462	-	0.159
=	2.044

Verici Dx Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Verici Dx's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx (Verici Dx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines